JP2020506703A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506703A5 JP2020506703A5 JP2019541414A JP2019541414A JP2020506703A5 JP 2020506703 A5 JP2020506703 A5 JP 2020506703A5 JP 2019541414 A JP2019541414 A JP 2019541414A JP 2019541414 A JP2019541414 A JP 2019541414A JP 2020506703 A5 JP2020506703 A5 JP 2020506703A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- chain variable
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims description 84
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 84
- 229940079593 drug Drugs 0.000 claims description 70
- 239000003814 drug Substances 0.000 claims description 70
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 54
- 108091007433 antigens Proteins 0.000 claims description 54
- 239000012634 fragment Substances 0.000 claims description 53
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 38
- 210000004027 cell Anatomy 0.000 claims description 33
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 26
- 125000005647 linker group Chemical group 0.000 claims description 26
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 239000003112 inhibitor Substances 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 150000003573 thiols Chemical group 0.000 claims description 18
- 238000004113 cell culture Methods 0.000 claims description 15
- 230000001268 conjugating effect Effects 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 150000003852 triazoles Chemical class 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 9
- -1 2,5 -Dioxopyrrolidine-1-yl Chemical group 0.000 claims description 8
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims description 8
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 8
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 8
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 8
- 201000006966 adult T-cell leukemia Diseases 0.000 claims description 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 8
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 229950001474 maitansine Drugs 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 claims description 4
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 claims description 4
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 4
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 claims description 4
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 102100024263 CD160 antigen Human genes 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 4
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 4
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 229920000134 Metallised film Polymers 0.000 claims description 4
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims description 4
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000006845 reticulosarcoma Diseases 0.000 claims description 4
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 238000005571 anion exchange chromatography Methods 0.000 claims description 3
- 229940125644 antibody drug Drugs 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 238000005277 cation exchange chromatography Methods 0.000 claims description 3
- 239000000562 conjugate Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 238000001728 nano-filtration Methods 0.000 claims description 3
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims description 2
- GWEVSJHKQHAKNW-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]disulfanyl]-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1C=CC=CN1N1C(=O)CCC1=O GWEVSJHKQHAKNW-UHFFFAOYSA-N 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 2
- 229940121819 ATPase inhibitor Drugs 0.000 claims description 2
- 108010027164 Amanitins Proteins 0.000 claims description 2
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100035793 CD83 antigen Human genes 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 239000012624 DNA alkylating agent Substances 0.000 claims description 2
- 230000005778 DNA damage Effects 0.000 claims description 2
- 231100000277 DNA damage Toxicity 0.000 claims description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 2
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102100029095 Exportin-1 Human genes 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 2
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 2
- 102100027670 Islet amyloid polypeptide Human genes 0.000 claims description 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 2
- 102000010638 Kinesin Human genes 0.000 claims description 2
- 108010063296 Kinesin Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims description 2
- 229940122277 RNA polymerase inhibitor Drugs 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 2
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 101150094313 XPO1 gene Proteins 0.000 claims description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- CIORWBWIBBPXCG-JZTFPUPKSA-N amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000001640 apoptogenic effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 230000022534 cell killing Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 108700002148 exportin 1 Proteins 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 102000043839 human CCR7 Human genes 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 210000003470 mitochondria Anatomy 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 230000025308 nuclear transport Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 239000000007 protein synthesis inhibitor Substances 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 238000006276 transfer reaction Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000000746 purification Methods 0.000 description 6
- 0 CC(N(C)[C@@](C)C(O[C@@](CC(N(C)c1cc(CC(C)=C/C=C/[C@]([C@@](C2)(N3)O)OC)cc(OC)c1*)=O)C(C)(C)O[C@](C)[C@]2OC3=N)=O)SS* Chemical compound CC(N(C)[C@@](C)C(O[C@@](CC(N(C)c1cc(CC(C)=C/C=C/[C@]([C@@](C2)(N3)O)OC)cc(OC)c1*)=O)C(C)(C)O[C@](C)[C@]2OC3=N)=O)SS* 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 101100008681 Glycine max DHPS1 gene Proteins 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000235648 Pichia Species 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- 241000223259 Trichoderma Species 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000000688 human artificial chromosome Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762454476P | 2017-02-03 | 2017-02-03 | |
| US62/454,476 | 2017-02-03 | ||
| PCT/IB2018/050639 WO2018142322A1 (en) | 2017-02-03 | 2018-02-01 | Anti-ccr7 antibody drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506703A JP2020506703A (ja) | 2020-03-05 |
| JP2020506703A5 true JP2020506703A5 (https=) | 2021-03-11 |
| JP7312111B2 JP7312111B2 (ja) | 2023-07-20 |
Family
ID=61283268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541414A Active JP7312111B2 (ja) | 2017-02-03 | 2018-02-01 | 抗ｃｃｒ７抗体薬物コンジュゲート |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11634497B2 (https=) |
| EP (1) | EP3577139A1 (https=) |
| JP (1) | JP7312111B2 (https=) |
| CN (1) | CN110248963B (https=) |
| AR (1) | AR110920A1 (https=) |
| AU (1) | AU2018215701B2 (https=) |
| BR (1) | BR112019015950A2 (https=) |
| CA (1) | CA3049639A1 (https=) |
| CL (2) | CL2019002144A1 (https=) |
| CO (1) | CO2019008209A2 (https=) |
| CR (1) | CR20190346A (https=) |
| CU (1) | CU24648B1 (https=) |
| EA (1) | EA201991763A1 (https=) |
| EC (1) | ECSP19054235A (https=) |
| IL (1) | IL267834B2 (https=) |
| JO (1) | JOP20190187A1 (https=) |
| MA (1) | MA51778A (https=) |
| MX (2) | MX2019009119A (https=) |
| MY (1) | MY194997A (https=) |
| PE (1) | PE20191328A1 (https=) |
| PH (1) | PH12019501773A1 (https=) |
| SA (1) | SA519402358B1 (https=) |
| SG (1) | SG11201906229QA (https=) |
| TW (2) | TWI839325B (https=) |
| UY (1) | UY37591A (https=) |
| WO (1) | WO2018142322A1 (https=) |
| ZA (1) | ZA201904218B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102447350B1 (ko) * | 2013-02-08 | 2022-09-23 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| JP7337698B2 (ja) | 2017-02-28 | 2023-09-04 | シージェン インコーポレイテッド | コンジュゲート化のためのシステイン突然変異抗体 |
| JP7607564B2 (ja) * | 2018-12-21 | 2024-12-27 | ノバルティス アーゲー | Ｐｍｅｌ１７に対する抗体及びその結合体 |
| IL312067B2 (en) | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
| KR20220092500A (ko) * | 2019-10-09 | 2022-07-01 | 캐터펄트 테라퓨틱스 비.브이. | 혈액 악성종양을 치료하기 위한 btk 억제제 및/또는 bcl2-억제제와의 조합 요법에서의 항-ccr7 항체의 용도 |
| JP7520972B2 (ja) * | 2019-10-25 | 2024-07-23 | ウーシー バイオロジクス アイルランド リミテッド | 新規抗ｃｄ４７抗体及びその使用 |
| US11555190B2 (en) | 2020-03-19 | 2023-01-17 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
| AU2021241682B2 (en) | 2020-03-27 | 2026-02-12 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle dystrophy |
| US20230181756A1 (en) * | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| MX2023001163A (es) | 2020-07-27 | 2023-02-22 | Tuojie Biotech Shanghai Co Ltd | Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo. |
| JP2023547499A (ja) * | 2020-11-06 | 2023-11-10 | ノバルティス アーゲー | 抗体Ｆｃ変異体 |
| US20240101673A1 (en) | 2021-02-03 | 2024-03-28 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| WO2022232016A2 (en) * | 2021-04-26 | 2022-11-03 | Memorial Sloan-Kettering Cancer Center | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| JP2025504419A (ja) | 2022-01-26 | 2025-02-12 | 上▲海▼▲邁▼晋生物医▲薬▼科技有限公司 | 抗ＣＤ７９ｂ抗体薬物複合体を含む医薬組成物及びその使用 |
| KR102748862B1 (ko) * | 2022-05-19 | 2025-01-02 | 국민대학교 산학협력단 | Ccr7의 활성 조절 항체 |
| AU2024299729A1 (en) | 2023-07-25 | 2026-02-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antibody-drug conjugate targeting c-met and medical use thereof |
| WO2025174274A1 (ru) * | 2024-02-16 | 2025-08-21 | Ярослав Леонидович КАМИНСКИЙ | Производные индолнафталенацетамидов и их применение |
Family Cites Families (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633410A (en) | 1898-09-22 | 1899-09-19 | George A Ames | Ice-cutter. |
| US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
| WO1992019244A2 (en) | 1991-05-01 | 1992-11-12 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2128208C (en) | 1992-11-17 | 2004-01-06 | Ronald Godiska | Novel seven transmembrane receptors |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6043551A (en) | 1997-09-30 | 2000-03-28 | Intel Corporation | Metal locking structures to prevent a passivation layer from delaminating |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6153441A (en) | 1998-02-17 | 2000-11-28 | Smithkline Beecham Corporation | Methods of screening for agonists and antagonists for human CCR7 receptor and CKβ-9 ligand and interaction thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| ES2205849T3 (es) | 1998-07-22 | 2004-05-01 | Osprey Pharmaceuticals Limited | Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares. |
| WO2000009151A1 (en) | 1998-08-17 | 2000-02-24 | Schering Corporation | Regulation of dendritic cell trafficking |
| ES2276708T3 (es) | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| WO2001038352A2 (en) | 1999-11-24 | 2001-05-31 | Schering Corporation | Methods of inhibiting metastasis |
| US6949243B1 (en) | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
| ATE344801T1 (de) | 1999-12-29 | 2006-11-15 | Immunogen Inc | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
| AU2001280891A1 (en) | 2000-08-01 | 2002-02-13 | Schering Corporation | Uses of mammalian genes and related reagents |
| US6411163B1 (en) | 2000-08-14 | 2002-06-25 | Intersil Americas Inc. | Transconductance amplifier circuit |
| AU2002251913A1 (en) | 2001-02-02 | 2002-08-19 | Millennium Pharmaceuticals, Inc. | Hybrid antibodies and uses thereof |
| CA2439279A1 (en) | 2001-02-28 | 2002-09-06 | Protein Design Labs, Inc. | Chemokine receptors and disease |
| US20020168358A1 (en) | 2001-04-30 | 2002-11-14 | Gladue Ronald P. | Treatment of T-cell mediated diseases |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| JP4233092B2 (ja) | 2001-06-07 | 2009-03-04 | ケモセントリックス， インコーポレイテッド | 細胞移動アッセイ |
| US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| ATE415413T1 (de) | 2002-07-15 | 2008-12-15 | Univ Princeton | Iap-bindende verbindungen |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| WO2004104574A2 (en) | 2003-05-23 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7) |
| ITRM20030386A1 (it) | 2003-08-05 | 2005-02-06 | Istituto Naz Per Le Malattie Infettive Lazz | Metodo e test diagnostici basati sull'analisi citofluorimetrica dei linfociti t antigene-specifici. |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
| US7932382B2 (en) | 2004-01-16 | 2011-04-26 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| WO2005094818A1 (en) | 2004-03-23 | 2005-10-13 | Genentech, Inc. | Azabicyclo-octane inhibitors of iap |
| RS52545B (sr) | 2004-04-07 | 2013-04-30 | Novartis Ag | Inhibitori protein apoptoze (iap) |
| US7274964B2 (en) | 2004-04-16 | 2007-09-25 | Bal Seal Engineering Co., Inc. | Use of an axial canted coil spring as an electrical contact to minimize resistivity variations under dynamic loads |
| BRPI0511350A (pt) | 2004-07-02 | 2007-12-04 | Genentech Inc | composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto |
| US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| EP1773348A4 (en) | 2004-07-12 | 2009-05-20 | Idun Pharmaceuticals Inc | TETRA PEPTIDE ANALOGS |
| AU2005274937B2 (en) | 2004-07-15 | 2011-08-18 | Medivir Ab | IAP binding compounds |
| US20080112934A1 (en) | 2004-11-24 | 2008-05-15 | Rafick-Pierre Sekaly | Methods To Identify, Prepare, And Use Naive T Cell Recent Thymic Emigrants |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| US20110166319A1 (en) | 2005-02-11 | 2011-07-07 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| CA2597407C (en) | 2005-02-11 | 2013-09-10 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| CN101171337A (zh) | 2005-03-09 | 2008-04-30 | 得克萨斯大学体系董事会 | 与基因表达的体内成像相关的方法和组合物 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1910828A4 (en) | 2005-07-01 | 2012-03-14 | Univ St Louis | PHOSPHOSPECTIVE CHEMOKIN RECEPTOR ANTIBODIES |
| WO2007003216A1 (en) * | 2005-07-06 | 2007-01-11 | Universidad Autónoma de Madrid | Anti-ccr7 receptor antibodies for the treatment of cancer |
| EP3539572A1 (en) | 2005-08-24 | 2019-09-18 | ImmunoGen, Inc. | Process for preparing maytansinoid antibody conjugates |
| US20090304721A1 (en) | 2005-09-07 | 2009-12-10 | Medlmmune, Inc | Toxin conjugated eph receptor antibodies |
| CA2624662A1 (en) | 2005-09-30 | 2007-04-12 | The Government Of The United States Of America, As Represented By The Se Cretary Of Health And Human Services | Methods and compositions for modulating immune tolerance |
| WO2007048022A2 (en) | 2005-10-21 | 2007-04-26 | Alexion Pharmaceuticals, Inc. | Antibody-polypeptide fusion proteins and methods for producing and using same |
| WO2007055823A2 (en) | 2005-10-28 | 2007-05-18 | Multispan, Inc. | Gpcr expressing cell lines and antibodies |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| BRPI0711237A2 (pt) | 2006-05-23 | 2011-08-23 | Vb Medicare Pvt Ltd | processo de purificação e recuperação de uma amida terciária a partir de uma composição lìquida aquosa |
| WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
| WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
| BRPI0720647A2 (pt) | 2006-12-29 | 2014-01-14 | Osprey Pharmaceuticals Usa Inc | Processos de seleção e produção de toxinas modificadas, conjugados contendo toxinas modificadas e usos dos mesmos |
| PE20130150A1 (es) | 2007-04-30 | 2013-02-27 | Genentech Inc | Inhibidores de las iap |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| EP2073009A1 (en) | 2007-12-19 | 2009-06-24 | Cell Med Research GMBH | Method for T, NK and NKT cells |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR20200058590A (ko) | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| EP2285403A2 (en) | 2008-05-14 | 2011-02-23 | Msm Protein Technologies, Inc. | Human monoclonal antibodies against human chemokine receptor ccr7 |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
| US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
| BRPI1010620B8 (pt) | 2009-06-03 | 2021-05-25 | Immunogen Inc | métodos de conjugação |
| AU2010270979B2 (en) | 2009-06-22 | 2015-04-23 | Medimmune, Llc | Engineered Fc regions for site-specific conjugation |
| EP2272977A1 (en) | 2009-07-08 | 2011-01-12 | Universite Libre De Bruxelles | Diagnostic method and kit for the detection of a lymphocytic variant of hypereosinophilic syndrome |
| US8276780B2 (en) | 2009-11-18 | 2012-10-02 | Snyder Industries, Inc. | Fitting torque arm restraint |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011123903A1 (en) | 2010-04-08 | 2011-10-13 | Adelaide Research & Innovation Pty Ltd | Chemokine receptor heteromultimers, compounds that bind thereto and uses thereof |
| AU2011309114B2 (en) * | 2010-09-28 | 2015-03-19 | Nb Health Laboratory Co., Ltd. | Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier |
| WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
| WO2012148547A1 (en) | 2011-02-24 | 2012-11-01 | The Schepens Eye Research Institute, Inc. | Compositions and methods for treating inflammatory conditions of the ocular surface |
| RS58367B1 (sr) | 2011-03-29 | 2019-03-29 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| MX2013011201A (es) | 2011-03-29 | 2013-12-16 | Immunogen Inc | Proceso para la elaboracion de conjugados de mejor homogeneidad. |
| WO2012172343A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating primary sclerosing cholangitis |
| WO2012172337A2 (en) | 2011-06-13 | 2012-12-20 | Ith Immune Therapy Holdings | Treating cardiovascular disease |
| ES2760300T3 (es) | 2011-06-13 | 2020-05-13 | Tla Targeted Immunotherapies Ab | Diagnóstico y tratamiento de la enfermedad inflamatoria del intestino y del síndrome del intestino irritable |
| EP3228631B1 (en) | 2011-06-13 | 2020-06-24 | TLA Targeted Immunotherapies AB | Treating respiratory conditions |
| ES2800316T3 (es) | 2011-06-13 | 2020-12-29 | Tla Targeted Immunotherapies Ab | Tratamiento del cáncer |
| RU2011130448A (ru) | 2011-07-22 | 2013-01-27 | Зао "Евроген" | Методы и наборы для увеличения разнообразия т-клеток |
| SG190466A1 (en) | 2011-11-18 | 2013-06-28 | Agency Science Tech & Res | Methods for diagnosis and/or prognosis of ovarian cancer |
| EP2814525A1 (en) | 2012-02-13 | 2014-12-24 | Cook Medical Technologies LLC | Medical devices for collecting pathogenic cells |
| WO2013179174A1 (en) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Lighting arrangement |
| EP2855520B1 (en) | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
| WO2013184200A1 (en) * | 2012-06-05 | 2013-12-12 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr7 |
| US20150307619A1 (en) | 2012-12-13 | 2015-10-29 | The Schepens Eye Research Institute, Inc. | Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors |
| WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| KR102447350B1 (ko) | 2013-02-08 | 2022-09-23 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
| JP6494533B2 (ja) * | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
| WO2014153114A1 (en) | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| NZ710929A (en) * | 2013-03-15 | 2018-02-23 | Novartis Ag | Antibody drug conjugates |
| EP2970483A2 (en) | 2013-03-15 | 2016-01-20 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
| US10132309B2 (en) | 2013-03-15 | 2018-11-20 | Integrated Designs, L.P. | Apparatus and method for the remote monitoring, viewing and control of a semiconductor process tool |
| AU2014312215B2 (en) * | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| WO2015033137A1 (en) | 2013-09-04 | 2015-03-12 | Imperial Innovations Limited | Biological methods and materials for use therein |
| GB201315748D0 (en) | 2013-09-04 | 2013-10-16 | Imp Innovations Ltd | Biological methods and materials for use therein |
| GB2518221A (en) | 2013-09-16 | 2015-03-18 | Sergej Michailovic Kiprijanov | Tetravalent antigen-binding protein molecule |
| GB2519786A (en) | 2013-10-30 | 2015-05-06 | Sergej Michailovic Kiprijanov | Multivalent antigen-binding protein molecules |
| BR112016012538A2 (pt) | 2013-12-17 | 2017-09-26 | Novartis Ag | peptídeos citotóxicos e conjugados dos mesmos |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| CA2940451A1 (en) | 2014-03-12 | 2015-09-17 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| EP3131558B1 (en) | 2014-04-16 | 2018-11-14 | Genovie AB | Regulatory t-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract |
| ES2895623T3 (es) * | 2014-05-22 | 2022-02-22 | Byondis Bv | Conjugación de sitio específico de fármacos enlazadores con anticuerpos y ADC resultantes |
| CN106573956A (zh) | 2014-06-13 | 2017-04-19 | 诺华股份有限公司 | 澳瑞他汀衍生物及其缀合物 |
| GB201419185D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resin |
| WO2016075670A1 (en) | 2014-11-14 | 2016-05-19 | Novartis Ag | Antibody drug conjugates |
| WO2016099483A1 (en) * | 2014-12-17 | 2016-06-23 | National Oilwell Dht L.P. | Method of pressure testing a wellbore |
| WO2016179472A2 (en) | 2015-05-07 | 2016-11-10 | University Of Maryland, Baltimore | Modulation of natural killer cell tolerance |
| EP3310813A1 (en) | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
| BR112018002877A2 (en) | 2015-08-10 | 2018-11-06 | Pepmab B.V. | humanized ccr7 receptor antibodies |
| WO2017134483A1 (en) * | 2016-02-01 | 2017-08-10 | Telefonaktiebolaget Lm Ericsson (Publ) | Reconfigurable optical modulator |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
-
2017
- 2017-06-16 JO JOP/2019/0187A patent/JOP20190187A1/ar unknown
-
2018
- 2018-02-01 CN CN201880009163.2A patent/CN110248963B/zh active Active
- 2018-02-01 MA MA051778A patent/MA51778A/fr unknown
- 2018-02-01 UY UY0001037591A patent/UY37591A/es not_active Application Discontinuation
- 2018-02-01 CA CA3049639A patent/CA3049639A1/en active Pending
- 2018-02-01 BR BR112019015950-9A patent/BR112019015950A2/pt not_active IP Right Cessation
- 2018-02-01 AU AU2018215701A patent/AU2018215701B2/en not_active Ceased
- 2018-02-01 CR CR20190346A patent/CR20190346A/es unknown
- 2018-02-01 PE PE2019001507A patent/PE20191328A1/es unknown
- 2018-02-01 MY MYPI2019003816A patent/MY194997A/en unknown
- 2018-02-01 TW TW107103559A patent/TWI839325B/zh not_active IP Right Cessation
- 2018-02-01 MX MX2019009119A patent/MX2019009119A/es unknown
- 2018-02-01 CU CU2019000072A patent/CU24648B1/es unknown
- 2018-02-01 EA EA201991763A patent/EA201991763A1/ru unknown
- 2018-02-01 JP JP2019541414A patent/JP7312111B2/ja active Active
- 2018-02-01 US US16/482,173 patent/US11634497B2/en active Active
- 2018-02-01 SG SG11201906229QA patent/SG11201906229QA/en unknown
- 2018-02-01 WO PCT/IB2018/050639 patent/WO2018142322A1/en not_active Ceased
- 2018-02-01 EP EP18707417.4A patent/EP3577139A1/en active Pending
- 2018-02-01 AR ARP180100236A patent/AR110920A1/es unknown
- 2018-02-01 IL IL267834A patent/IL267834B2/en unknown
- 2018-02-01 TW TW111137885A patent/TW202323292A/zh unknown
-
2019
- 2019-06-27 ZA ZA2019/04218A patent/ZA201904218B/en unknown
- 2019-07-29 CO CONC2019/0008209A patent/CO2019008209A2/es unknown
- 2019-07-29 EC ECSENADI201954235A patent/ECSP19054235A/es unknown
- 2019-07-30 CL CL2019002144A patent/CL2019002144A1/es unknown
- 2019-07-30 PH PH12019501773A patent/PH12019501773A1/en unknown
- 2019-07-31 SA SA519402358A patent/SA519402358B1/ar unknown
- 2019-07-31 MX MX2022011732A patent/MX2022011732A/es unknown
-
2023
- 2023-02-03 US US18/164,519 patent/US12180291B2/en active Active
-
2024
- 2024-05-16 CL CL2024001473A patent/CL2024001473A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506703A5 (https=) | ||
| JP7458399B2 (ja) | 抗クローディン抗体及びそれらの使用 | |
| JP7654757B2 (ja) | 抗トランスフェリン受容体抗体およびその使用 | |
| CN113302207B (zh) | Cd38和icam1抗体及其用途 | |
| CN109310885B (zh) | NaPi2b靶向抗体-药物缀合物及其使用方法 | |
| TWI901692B (zh) | 抗ｂｃｍａ抗體-藥物軛合物及其使用方法 | |
| CN114375296A (zh) | 核酸多肽组合物及其用途 | |
| JP2023527638A (ja) | 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法 | |
| US20210100838A1 (en) | Human antibodies that bind and are internalized by mesothelioma and other cancer cells | |
| US12194106B2 (en) | Antibodies targeting LIV-1 and uses thereof | |
| EP4674438A1 (en) | Antibody-drug conjugate containing anti-cd138 antibody | |
| US12180276B2 (en) | Antibodies and antibody-drug conjugates targeting claudin 6 | |
| TW202535936A (zh) | 靶向liv-1之抗體及其用途 | |
| RU2019126481A (ru) | Конъюгаты антитела к ccr7 и лекарственного средства | |
| WO2025167838A1 (en) | Antibodies, antibody-drug conjugates, and producing methods thereof | |
| TW202535953A (zh) | 靶向密連蛋白６之抗體及抗體－藥物結合物 | |
| KR20250021381A (ko) | 인테그린 베타-2를 표적화하는 항체 | |
| WO2025232773A1 (zh) | 药物组合及其用途 | |
| HK40059021A (en) | Anti-claudin antibodies and uses thereof | |
| TW202434626A (zh) | 位點特異性工程化之半胱胺酸抗體藥物結合物 | |
| HK40059021B (zh) | 抗-紧密连接蛋白抗体及其用途 | |
| KR20220143904A (ko) | 사람 4-1bb 항진제 항체 및 이의 사용 방법 | |
| RU2021121383A (ru) | Антитела к рмel17 и конъюгаты на их основе |